Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Dermot Cox. (2021) How not to discover a drug - integrins. Expert Opinion on Drug Discovery 16:2, pages 197-211.
Read now
Read now
Hao Li, Shi-Ying Huang, Fang-Hong Shi, Zhi-Chun Gu, Shun-Guo Zhang & Ji-Fu Wei. (2018) α4β7 integrin inhibitors: a patent review. Expert Opinion on Therapeutic Patents 28:12, pages 903-917.
Read now
Read now
Articles from other publishers (25)
Chong He, Wenbo Xiu, Qinyuan Chen, Kun Peng, Xiong Zhu, Zuo Wang, Xiang Xu, Yang Chen, Gao Zhang, Jing Fu, Qiwei Dong, Xiaoqiong Wu, An Li, Donghua Liu, Yanping Gao, Jinxia Wang, Zhao Wang, Bolin Deng, Ping Shuai, Caiping Gao, Yilian Chen, Ling Yu & Fang Lu. (2023)
Gut-licensed β7
+
CD4
+
T cells contribute to progressive retinal ganglion cell damage in glaucoma
. Science Translational Medicine 15:707.
Crossref
Crossref
Ruixia Li, Xiaofei Li, He Zhou, Yanting Shi, Fang Wang, Tong Wu & Jie Liang. (2023) Successful treatment of a refractory intestinal Behcet’s disease with an oncology history by Vedolizumab: a case report and literature review. Frontiers in Immunology 14.
Crossref
Crossref
Xinrui Wang, Shuai Quan, Jingyang Li, Ying Liu, Huageng Sun, Jingze Zhang & Dailin Liu. (2022) Protective Effects of Grape Seed Proanthocyanidin Extract in Preventing DSS
Induced Ulcerative Colitis Based on Pharmacodynamic, Pharmacokinetic and Tissue
Distribution. Current Drug Metabolism 23:6, pages 496-505.
Crossref
Crossref
Athos Bousvaros. 2022. Management of Inpatient Inflammatory Bowel Disease. Management of Inpatient Inflammatory Bowel Disease
225
246
.
Tommaso Innocenti, Jenny Roselli, Erica N. Lynch, Pasquale Apolito, Laura Parisio, Siro Bagnoli, Giuseppe Macrì, Francesca Rogai, Mirko Tarocchi, Stefano Milani, Andrea Galli, Monica Milla & Gabriele Dragoni. (2021) Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 33:1S, pages e574-e579.
Crossref
Crossref
Eva de Berranger, Amandine Charbonnier, Elise Davy, Caroline Dendonker, Virginie Denis, Déborah Desmier, Carole Farrugia, Sarah Guenounou, Yoann Guilbert, Edgar Jost, Alexandra L’hostette, Fanny Rialland, Sophie Taque, Nabil Yafour, David Seguy & Ibrahim Yakoub Agha. (2021) Prise en charge de la GVH digestive aiguë : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer 108:12, pages S30-S38.
Crossref
Crossref
Fangwen Zou, David Faleck, Anusha Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S Ernstoff, Isabella C Glitza Oliva, Stephen Hanauer, Jennifer McQuade, Michel Obeid, Amishi Shah, David M Richards, Elad Sharon, Jedd Wolchok, John Thompson & Yinghong Wang. (2021) Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. Journal for ImmunoTherapy of Cancer 9:11, pages e003277.
Crossref
Crossref
Cecilia T Costiniuk, Talat Bessissow, Stéphane Isnard & Jean-Pierre Routy. (2021) Use of various immunotherapies for refractory ulcerative colitis in a person living with HIV: a case report. Oxford Medical Case Reports 2021:1.
Crossref
Crossref
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla & M.A. Martínez-Vázquez. (2021) Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. Revista de Gastroenterología de México (English Edition) 86:1, pages 70-85.
Crossref
Crossref
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla & M.A. Martínez-Vázquez. (2021) Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal. Revista de Gastroenterología de México 86:1, pages 70-85.
Crossref
Crossref
Bergithe E. Oftedal & Anette S. B. Wolff. (2020) New era of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology 92:5.
Crossref
Crossref
Elissa Lin & Seymour Katz. (2020) Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab. Inflammatory Bowel Diseases 26:5, pages e44-e44.
Crossref
Crossref
Michael W. Winter & Joel V. Weinstock. 2020. The Autoimmune Diseases. The Autoimmune Diseases
871
894
.
Sebastian Zundler, Emily Becker, Lisa Lou Schulze & Markus F Neurath. (2019) Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 68:9, pages 1688-1700.
Crossref
Crossref
Chimezie Mbachi, Bashar Attar, Olamide Oyenubi, Wang Yuchen, Aisien Efesomwan, Isaac Paintsil, Mathew Madhu, Oyintayo Ajiboye, C. Roberto Simons-Linares, William E. Trick & Vikram Kotwal. (2019) Association between cannabis use and complications related to ulcerative colitis in hospitalized patients. Medicine 98:32, pages e16551.
Crossref
Crossref
E. B. Kornilova, K. I. Polyakova, T. V. Shkurko, O. V. Knyazev, A. D. Ermolaeva, M. V. Davydovskaya, T. N. Ermolaeva & A. G. Fisun. (2019) Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. Dokazatel'naya gastroenterologiya 8:3, pages 55.
Crossref
Crossref
Mathieu Uzzan, Minami Tokuyama, Adam K. RosensteinCostin TomescuIvo N. SahBandar, Huaibin M. Ko, Louise LeyreAnupa Chokola, Emma Kaplan-LewisGabriela RodriguezAkihiro SekiMichael J. CorleyJudith Aberg, Annalena La PorteEun-young Park, Hideki Ueno, Ioannis OikonomouItai Doron, Iliyan D. Iliev, Benjamin K. Chen, Jennifer LuiTimothy W. Schacker, Glaucia C. Furtado, Sergio A. LiraJean-Frederic ColombelAmir Horowitz, Jean K. Lim, Nicolas Chomont, Adeeb H. Rahman, Luis J. Montaner, Lishomwa C. NdhlovuSaurabh Mehandru. (2018) Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals. Science Translational Medicine 10:461.
Crossref
Crossref
Lydia C T Buer, Marte L Høivik, David J Warren, Asle W Medhus & Bjørn A Moum. (2018) Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflammatory Bowel Diseases 24:5, pages 997-1004.
Crossref
Crossref
James Arthos, Claudia Cicala, Fatima Nawaz, Siddappa N. Byrareddy, Francois Villinger, Philip J. Santangelo, Aftab A. Ansari & Anthony S. Fauci. (2018) The Role of Integrin α4β7 in HIV Pathogenesis and Treatment. Current HIV/AIDS Reports 15:2, pages 127-135.
Crossref
Crossref
Delila Pouldar, Ashley Elsensohn, Francesca Ortenzio, Jessica Shiu, Michael McLeod & Sébastien de Feraudy. (2018) Nodular Vasculitis in a Patient With Crohn's Disease on Vedolizumab. The American Journal of Dermatopathology 40:3, pages e36-e37.
Crossref
Crossref
Pieter Hindryckx & Gregor Novak. (2018) Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. Best Practice & Research Clinical Gastroenterology 32-33, pages 9-15.
Crossref
Crossref
Tobias Derfuss & Ludwig Kappos. (2017) PML risk and natalizumab: the elephant in the room. The Lancet Neurology 16:11, pages 864-865.
Crossref
Crossref
Pieter Hindryckx, Gregor Novak, Stefanos Bonovas, Laurent Peyrin-Biroulet & Silvio Danese. (2017) Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease. Clinical Pharmacology & Therapeutics 102:4, pages 633-641.
Crossref
Crossref
Vera Denmark. (2017) Safety and Immunogenicity of Biologic Therapy in Inflammatory Bowel Disease. Hospital Medicine Clinics 6:3, pages 425-435.
Crossref
Crossref
Fangwen Zou, David M. Faleck, Anusha S. Thomas, Jessica Harris, Deepika Satish, Xuemei Wang, Aline Charabaty, Marc S. Ernstoff, Isabella C. Glitza Oliva, Stephen B. Hanauer, Jennifer L. McQuade, Michel Obeid, Amishi Y. Shah, David M. Richards, Elad Sharon, Jedd D. Wolchok, John A. Thompson & Yinghong Wang. (2021) Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. SSRN Electronic Journal.
Crossref
Crossref